Class I phosphoinositide 3-kinase isoform (PI3K (Class I) isoform)

Class I phosphoinositide 3-kinase isoform refers to one of four closely related catalytic subunits—PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ—which are key enzymes in the PI3K/AKT/mTOR signaling pathway[1][4][5]. Each isoform is encoded by distinct genes (PIK3CA, PIK3CB, PIK3CG, PIK3CD) and forms a heterodimer with a regulatory subunit[1][5][6]. These lipid kinases phosphorylate phosphatidylinositol-4,5-bisphosphate (PIP2) to generate PIP3, a second messenger; this leads to activation of AKT and downstream signaling pathways that regulate many physiological processes, including cell growth, proliferation, survival, metabolism, and immune responses[1][5]. The isoforms differ in expression patterns—PI3Kα and PI3Kβ are ubiquitous, while PI3Kγ and PI3Kδ are enriched in immune cells[1][5]. Mutations (especially in PIK3CA) or abnormal activity of these enzymes is common in cancer and associated with tumorigenesis and therapy resistance[1][5]. Selective inhibitors for individual isoforms are now clinically approved or in development for malignancies (e.g., idelalisib for CLL and follicular lymphoma, alpelisib for PIK3CA-mutated breast cancer), and dual inhibition (e.g., duvelisib) enables targeting both tumoral and immune microenvironments[1][4][5]. Major therapeutic challenges include isoform redundancy, compensatory pathway activation, and toxicity related to inhibition in non-tumor tissues[1][3][4]. PI3K pathway components are also evaluated as biomarkers to identify responsive patient populations and for efficacy monitoring[1][5].

Other names

Class I PI3KPI3K class Iphosphatidylinositol 3-kinase class IPI3Kα (PIK3CA)PI3Kβ (PIK3CB)PI3Kγ (PIK3CG)PI3Kδ (PIK3CD)p110αp110βp110γp110δ

Isoform-selective inhibition (e.g., PI3Kδ-, PI3Kα-, PI3Kβ-specific), pan-PI3K inhibition, dual PI3K/mTOR inhibition; reduction of PI3K pathway activation, impairment of AKT/mTOR downstream signaling, inhibition of tumor cell proliferation and survival, immune cell modulation